Tci Wealth Advisors, Inc. Viking Therapeutics, Inc. Transaction History

Tci Wealth Advisors, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$3.0 - $4.88 $2,520 - $4,099	-840 Reduced 73.68%	300 $1,000
Q4 2021 Jan 24, 2022	BUY	$4.6 - $6.72 $3,863 - $5,644	840 Added 280.0%	1,140 $5,000
Q2 2021 Aug 02, 2021	SELL	$5.19 - $6.73 $519 - $673	-100 Reduced 25.0%	300 $2,000
Q4 2020 Jan 21, 2021	SELL	$5.3 - $6.71 $530 - $671	-100 Reduced 20.0%	400 $2,000
Q3 2020 Oct 20, 2020	SELL	$5.73 - $8.11 $2,292 - $3,244	-400 Reduced 44.44%	500 $3,000
Q4 2019 Jan 27, 2020	SELL	$6.38 - $8.73 $1,914 - $2,619	-300 Reduced 25.0%	900 $7,000
Q3 2019 Oct 17, 2019	BUY	$6.55 - $8.6 $655 - $860	100 Added 9.09%	1,200 $8,000
Q2 2019 Jul 23, 2019	SELL	$7.67 - $10.63 $767 - $1,063	-100 Reduced 8.33%	1,100 $9,000
Q1 2019 Apr 11, 2019	SELL	$7.58 - $9.94 $2,274 - $2,982	-300 Reduced 20.0%	1,200 $12,000
Q4 2018 Jan 17, 2019	BUY	$7.16 - $16.21 $2,148 - $4,863	300 Added 25.0%	1,500 $11,000
Q3 2018 Nov 02, 2018	BUY	$9.7 - $19.65 $3,879 - $7,859	400 Added 50.0%	1,200 $21,000
Q2 2018 Jul 27, 2018	BUY	$3.88 - $12.74 $1,940 - $6,370	500 Added 166.67%	800 $8,000
Q1 2018 Apr 30, 2018	BUY	$4.11 - $6.93 $1,233 - $2,079	300 New	300 $1,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.94B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.